Zobrazeno 1 - 10
of 743
pro vyhledávání: '"William J. Catalona"'
Autor:
Ryan Sutherland, Cary P. Gross, Xiaomei Ma, Farah Jeong, Tyler M. Seibert, Matthew R. Cooperberg, William J. Catalona, Shellie D. Ellis, Stacy Loeb, Dena Schulman‐Green, Michael S. Leapman
Publikováno v:
BJUI Compass, Vol 5, Iss 6, Pp 593-601 (2024)
Abstract Introduction Although prostate magnetic resonance imaging (MRI) is commonly used in the diagnosis, staging and active surveillance of prostate cancer, little is known about patient perspectives on MRI. Methods We performed a qualitative stud
Externí odkaz:
https://doaj.org/article/a716092646f0417b8cff9026b974b943
Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer
Autor:
Michael S. Leapman, Ryan Sutherland, Cary P. Gross, Xiaomei Ma, Tyler M. Seibert, Matthew R. Cooperberg, William J. Catalona, Stacy Loeb, Dena Schulman‐Green
Publikováno v:
BJUI Compass, Vol 5, Iss 1, Pp 142-149 (2024)
Abstract Background Tissue‐based gene expression (genomic) tests provide estimates of prostate cancer aggressiveness and are increasingly used for patients considering or engaged in active surveillance. However, little is known about patient experi
Externí odkaz:
https://doaj.org/article/a14dc37891e3489084198101c440dd61
Autor:
Benjamin H. Press, Tashzna Jones, Olamide Olawoyin, Soum D. Lokeshwar, Syed N. Rahman, Ghazal Khajir, Daniel W. Lin, Matthew R. Cooperberg, Stacy Loeb, Burcu F. Darst, Yingye Zheng, Ronald C. Chen, John S. Witte, Tyler M. Seibert, William J. Catalona, Michael S. Leapman, Preston C. Sprenkle
Publikováno v:
European Urology Open Science, Vol 37, Iss , Pp 113-119 (2022)
Background: Although the Decipher genomic classifier has been validated as a prognostic tool for several prostate cancer endpoints, little is known about its role in assessing the risk of biopsy reclassification for patients on active surveillance, a
Externí odkaz:
https://doaj.org/article/8904559f3f5c425790c10990081991fc
Autor:
Yu Jiang, Travis J. Meyers, Adaeze A. Emeka, Lauren Folgosa Cooley, Phillip R. Cooper, Nicola Lancki, Irene Helenowski, Linda Kachuri, Daniel W. Lin, Janet L. Stanford, Lisa F. Newcomb, Suzanne Kolb, Antonio Finelli, Neil E. Fleshner, Maria Komisarenko, James A. Eastham, Behfar Ehdaie, Nicole Benfante, Christopher J. Logothetis, Justin R. Gregg, Cherie A. Perez, Sergio Garza, Jeri Kim, Leonard S. Marks, Merdie Delfin, Danielle Barsa, Danny Vesprini, Laurence H. Klotz, Andrew Loblaw, Alexandre Mamedov, S. Larry Goldenberg, Celestia S. Higano, Maria Spillane, Eugenia Wu, H. Ballentine Carter, Christian P. Pavlovich, Mufaddal Mamawala, Tricia Landis, Peter R. Carroll, June M. Chan, Matthew R. Cooperberg, Janet E. Cowan, Todd M. Morgan, Javed Siddiqui, Rabia Martin, Eric A. Klein, Karen Brittain, Paige Gotwald, Daniel A. Barocas, Jeremiah R. Dallmer, Jennifer B. Gordetsky, Pam Steele, Shilajit D. Kundu, Jazmine Stockdale, Monique J. Roobol, Lionne D.F. Venderbos, Martin G. Sanda, Rebecca Arnold, Dattatraya Patil, Christopher P. Evans, Marc A. Dall’Era, Anjali Vij, Anthony J. Costello, Ken Chow, Niall M. Corcoran, Soroush Rais-Bahrami, Courtney Phares, Douglas S. Scherr, Thomas Flynn, R. Jeffrey Karnes, Michael Koch, Courtney Rose Dhondt, Joel B. Nelson, Dawn McBride, Michael S. Cookson, Kelly L. Stratton, Stephen Farriester, Erin Hemken, Walter M. Stadler, Tuula Pera, Deimante Banionyte, Fernando J. Bianco, Jr., Isabel H. Lopez, Stacy Loeb, Samir S. Taneja, Nataliya Byrne, Christopher L. Amling, Ann Martinez, Luc Boileau, Franklin D. Gaylis, Jacqueline Petkewicz, Nicholas Kirwen, Brian T. Helfand, Jianfeng Xu, Denise M. Scholtens, William J. Catalona, John S. Witte
Publikováno v:
HGG Advances, Vol 3, Iss 1, Pp 100070- (2022)
Summary: Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active
Externí odkaz:
https://doaj.org/article/dd671a3166f5492e9f3db2429cd59265
Autor:
Phillippa J. Neville, David V. Contit, Pamela L. Paris, Howard Levint, William J. Catalona, Brian K. Suarez, John S. Wittet, Graham Casey
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 4, Iss 5, Pp 424-431 (2002)
The biologic aggressiveness of prostate tumors is an important indicator of prognosis. Chromosome 7g32-q33 was recently reported to show linkage to more aggressive prostate cancer, based on Gleason score, in a large sibling pair study. We report conf
Externí odkaz:
https://doaj.org/article/6bc4ca31dffc431c974f50fedff56fb2
Autor:
Stacy Loeb, William J. Catalona
Publikováno v:
Therapeutic Advances in Urology, Vol 6 (2014)
A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI),
Externí odkaz:
https://doaj.org/article/25f592a721cf4f10bc0ec280630f06eb
Autor:
Michael S. Leapman, Rong Wang, Stacy Loeb, Tyler M. Seibert, Franklin D. Gaylis, Ben Lowentritt, Gordon A. Brown, Ronald Chen, Daniel Lin, John Witte, Matthew R. Cooperberg, William J. Catalona, Cary P. Gross, Xiaomei Ma
Publikováno v:
Journal of Urology. 209:710-718
Autor:
Kelvin A. Moses, Preston C. Sprenkle, Clinton Bahler, Geoffrey Box, Sigrid V. Carlsson, William J. Catalona, Douglas M. Dahl, Marc Dall’Era, John W. Davis, Bettina F. Drake, Jonathan I. Epstein, Ruth B. Etzioni, Thomas A. Farrington, Isla P. Garraway, David Jarrard, Eric Kauffman, Deborah Kaye, Adam S. Kibel, Chad A. LaGrange, Paul Maroni, Lee Ponsky, Brian Reys, Simpa S. Salami, Alejandro Sanchez, Tyler M. Seibert, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Mark D. Tyson, Neha Vapiwala, Robert Wake, Samuel Washington, Alice Yu, Bertram Yuh, Ryan A. Berardi, Deborah A. Freedman-Cass
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:236-246
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guideline
Autor:
John S. Witte, Benjamin A. Rybicki, William J. Catalona, Brian T. Helfand, Dhananjay Chitale, Albert M. Levin, Yalei Chen, Vy Ngo, Jeffrey P. Simko, Joel A. Mefford, Rémi Kazma, Niall J. Cardin, Thomas J. Hoffmann, Pamela L. Paris, Karla J. Lindquist
Allele frequencies for 128 ancestry informative single nucleotide polymorphisms, with correlations (r values) between Structure model estimates and actual allele frequencies for our 24 African American (AA) patients, plus 146 other AA and 204 Europea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040eb4f60691274aaf64a569bade804f
https://doi.org/10.1158/0008-5472.22410402
https://doi.org/10.1158/0008-5472.22410402
Autor:
John S. Witte, Benjamin A. Rybicki, William J. Catalona, Brian T. Helfand, Dhananjay Chitale, Albert M. Levin, Yalei Chen, Vy Ngo, Jeffrey P. Simko, Joel A. Mefford, Rémi Kazma, Niall J. Cardin, Thomas J. Hoffmann, Pamela L. Paris, Karla J. Lindquist
Individual patient Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) scores and test results, with and without copy-neutral losses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::085134039470d4f156c1e5cb77584e05
https://doi.org/10.1158/0008-5472.22410393
https://doi.org/10.1158/0008-5472.22410393